A single-institution experience with the Optilume Urethral Drug Coated Balloon for management of urethral stricture disease
DCB offers a safe and less invasive treatment for both treatment-naïve and recurrent urethral strictures with paclitaxel coating to prevent recurrence. Repeat intervention was not required for 90.7% of our cohort within an average follow-up duration of 9 months postoperatively. As DCB grows in clinical use, investigation into its long-term efficacy is justified.
Authors
- Mary Soyster (ORCID: https://orcid.org/0000-0001-6700-8662)
- Peter J. Arnold (ORCID: https://orcid.org/0000-0002-9922-0702)
- Ramzy T. Burns (ORCID: https://orcid.org/0009-0005-6610-4560)
- Ashorne K. Mahenthiran (ORCID: https://orcid.org/0000-0003-3409-2460)
- Harrison Love (ORCID: https://orcid.org/0000-0003-3066-3174)
- Matthew J. Mellon (ORCID: https://orcid.org/0000-0003-4823-4503)
- Morgan Black (ORCID: https://orcid.org/0000-0002-2762-1937)
Institutions
- Indiana University – Purdue University Indianapolis (US)
Publication Details
- Journal
- Translational Andrology and Urology
- Published
- 2024-08-01
- DOI
- https://doi.org/10.21037/tau-24-104
- Citations
- 10
- Primary Topic
- Urological Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 5.35